New Anti-Viral Drug Induces Significant Decrease in HBsAg in Hepatitis B
In this MEDtalk, Geoffrey Dusheiko, Kings College Hospital, and University College London, presents a new anti-viral drug class that may act as a new proxy for treatment and better classification of HBV patients. He also discussed the latest approaches to treating and managing HBV in this MEDtalk.
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in